NOVARTIS

The Novartis share fell by more than ten percent after a trial flop for a drug against the muscle disease myotonic dystrophy, prompting analysts to question the group's long-term growth targets. Novartis dragged down the entire healthcare sector; the Stoxx Europe 600 Health Care dropped more than two percent, and Sandoz also closed slightly down. Overall, European markets moved little, the EuroStoxx 50 closed marginally higher, while rising oil prices and upcoming interest-rate decisions left investors cautious. » Más en finanzen.net

Novartis’s phase‑III HARBOR study of del‑desiran for myotonic dystrophy type 1 failed to meet its primary endpoint and triggered a broad sell‑off across the sector. Sarepta fell sharply in premarket trading as investors reassessed the prospects for SRP‑1003 — also an siRNA targeting DMPK RNA but with a different mechanism of action. The decline was exacerbated by an already weak biotech environment, lowered revenue expectations for 2026, and ongoing regulatory uncertainty at Sarepta. » Más en de.investing.com

Novartis has begun a randomized, double-blind phase‑2a/b trial of the VAV1‑targeting molecular glue MRT‑6160 in patients with Sjögren’s syndrome to determine efficacy, safety and the phase‑3 dose. At the first patient visit Novartis will pay Monte Rosa Therapeutics a milestone payment of $50 million. Novartis holds worldwide exclusive rights for development, manufacturing and commercialization; Monte Rosa can receive up to $2.1 billion in milestones, will participate in phase‑3 funding and will receive 30% of U.S. profits plus tiered royalties outside the U.S. » Más en de.investing.com